Prothena公司
77 Sir John Rogerson’s Quay
Block C Grand Canal Docklands
Dublin D02 VK60
Ireland
353 1 236 2500
https://www.prothena.com
版塊: Healthcare
行業: Biotechnology
全職員工: 173
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Dr. Gene G. Kinney Ph.D. | President, CEO & Director | 1M | 1.97M | 1969 |
| Mr. Tran B. Nguyen M.B.A. | CFO & Chief Strategy Officer | 830.14k | 5.92M | 1974 |
| Mr. Brandon S. Smith | Chief Operating Officer | 757.79k | 1.07M | 1975 |
| Ms. Carol D. Karp | Chief Regulatory Officer | 701.48k | 2.1M | 1953 |
| Dr. Hideki Garren M.D., Ph.D. | Chief Medical Officer | 808.71k | 1.09M | 1965 |
| Ms. Karin L. Walker CPA | Chief Accounting Officer & Controller | 無 | 無 | 1963 |
| Dr. Wagner M. Zago | Chief Scientific Officer | 478.79k | 無 | 1973 |
| Mr. Mark C. Johnson C.F.A. | Vice President of Investor Relations | 無 | 無 | 無 |
| Mr. Michael J. Malecek | Chief Legal Officer | 588.25k | 無 | 1966 |
| Mr. David A. Ford | Chief People Officer | 無 | 無 | 1970 |
描述
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.
公司管治
截至 2024年5月1日 止，Prothena公司 的 ISS 管治質素評分為 4。 Pillar 分數正在審核中：7；董事會：4；股東權利：3；現金賠償：5。
